Search Results

There are 9338 results for: content related to: Neuropsychometric correlates of efavirenz pharmacokinetics and pharmacogenetics following a single oral dose

  1. You have free access to this content
    Pharmacogenetics of plasma efavirenz exposure in HIV-infected adults and children in South Africa

    British Journal of Clinical Pharmacology

    Volume 80, Issue 1, July 2015, Pages: 146–156, Phumla Z. Sinxadi, Paul D. Leger, Helen M. McIlleron, Peter J. Smith, Joel A. Dave, Naomi S Levitt, Gary Maartens and David W. Haas

    Version of Record online : 28 MAY 2015, DOI: 10.1111/bcp.12590

  2. Mechanism of Efavirenz Influence on Methadone Pharmacokinetics and Pharmacodynamics

    Clinical Pharmacology & Therapeutics

    Volume 91, Issue 4, April 2012, Pages: 673–684, E D Kharasch, D Whittington, D Ensign, C Hoffer, P S Bedynek, S Campbell, K Stubbert, A Crafford, A London and T Kim

    Version of Record online : 7 MAR 2012, DOI: 10.1038/clpt.2011.276

  3. Long-Term Efavirenz Autoinduction and Its Effect on Plasma Exposure in HIV Patients

    Clinical Pharmacology & Therapeutics

    Volume 88, Issue 5, November 2010, Pages: 676–684, E Ngaimisi, S Mugusi, O M Minzi, P Sasi, K-D Riedel, A Suda, N Ueda, M Janabi, F Mugusi, W E Haefeli, J Burhenne and E Aklillu

    Version of Record online : 29 SEP 2010, DOI: 10.1038/clpt.2010.172

  4. You have full text access to this OnlineOpen article
    Pharmacokinetic and Pharmacodynamic Comparison of Once-Daily Efavirenz (400 mg vs. 600 mg) in Treatment-Naïve HIV-Infected Patients: Results of the ENCORE1 Study

    Clinical Pharmacology & Therapeutics

    Volume 98, Issue 4, October 2015, Pages: 406–416, L Dickinson, J Amin, L Else, M Boffito, D Egan, A Owen, S Khoo, D Back, C Orrell, A Clarke, M Losso, P Phanuphak, D Carey, DA Cooper, S Emery and R Puls2, on behalf of the ENCORE1 Study Group

    Version of Record online : 14 JUL 2015, DOI: 10.1002/cpt.156

  5. Pharmacokinetics of Efavirenz When Co-administered With Rifampin in TB/HIV Co-infected Patients: Pharmacogenetic Effect of CYP2B6 Variation

    The Journal of Clinical Pharmacology

    Volume 48, Issue 9, September 2008, Pages: 1032–1040, Dr Awewura Kwara, Dr Margaret Lartey, Mr Kwamena W. Sagoe, Dr Fafa Xexemeku, Dr Ernest Kenu, Dr Joseph Oliver-Commey, Dr Vincent Boima, Mr Augustine Sagoe, Dr Isaac Boamah, Mr David J. Greenblatt and Dr Michael H. Court

    Version of Record online : 7 MAR 2013, DOI: 10.1177/0091270008321790

  6. Successful Use of Reduced-Dose Efavirenz in a Patient with Human Immunodeficiency Virus Infection: Case Report and Review of the Literature

    Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

    Volume 28, Issue 6, June 2008, Pages: 782–787, Dr. Mauro S. Torno, Dr. Mallory D. Witt, Dr. Akihiko Saitoh and Dr. Courtney V. Fletcher

    Version of Record online : 6 JAN 2012, DOI: 10.1592/phco.28.6.782

  7. Compartment-Specific Gene Regulation of the CAR Inducer Efavirenz In Vivo

    Clinical Pharmacology & Therapeutics

    Volume 92, Issue 1, July 2012, Pages: 103–111, H E Meyer zu Schwabedissen, S Oswald, C Bresser, A Nassif, C Modess, Z Desta, E T Ogburn, M Marinova, D Lütjohann, C Spielhagen, M Nauck, H K Kroemer and W Siegmund

    Version of Record online : 16 MAY 2012, DOI: 10.1038/clpt.2012.34

  8. Pharmacokinetic interaction between efavirenz and dual protease inhibitors in healthy volunteers

    Biopharmaceutics & Drug Disposition

    Volume 29, Issue 2, January 2008, Pages: 91–101, Qing Ma, Alan Forrest, Susan L. Rosenkranz, Michael F. Para, Kevin E. Yarasheski, Richard C. Reichman and Gene D. Morse

    Version of Record online : 27 NOV 2007, DOI: 10.1002/bdd.597

  9. Induction of CYP2C19 and CYP3A Activity Following Repeated Administration of Efavirenz in Healthy Volunteers

    Clinical Pharmacology & Therapeutics

    Volume 91, Issue 3, March 2012, Pages: 475–482, V Michaud, E Ogburn, N Thong, A O Aregbe, T C Quigg, D A Flockhart and Z Desta

    Version of Record online : 8 FEB 2012, DOI: 10.1038/clpt.2011.249

  10. You have free access to this content
    Biowaiver monographs for immediate release solid oral dosage forms: Efavirenz

    Journal of Pharmaceutical Sciences

    Volume 102, Issue 2, February 2013, Pages: 318–329, Rodrigo Cristofoletti, Anita Nair, Bertil Abrahamsson, D. W. Groot, Sabine Kopp, Peter Langguth, James E. Polli, Vinod P. Shah and Jennifer B. Dressman

    Version of Record online : 22 NOV 2012, DOI: 10.1002/jps.23380

  11. Pharmacokinetic Interaction Between Efavirenz and Carbamazepine After Multiple-Dose Administration in Healthy Subjects

    The Journal of Clinical Pharmacology

    Volume 48, Issue 8, August 2008, Pages: 948–956, Ping Ji, Dr Bharat Damle, Dr Jingdong Xie, Dr Steve E. Unger, Dennis M. Grasela and Sanjeev Kaul

    Version of Record online : 7 MAR 2013, DOI: 10.1177/0091270008319792

  12. Impact of Efavirenz on Intestinal Metabolism and Transport: Insights From an Interaction Study With Ezetimibe in Healthy Volunteers

    Clinical Pharmacology & Therapeutics

    Volume 91, Issue 3, March 2012, Pages: 506–513, S Oswald, H E Meyer zu Schwabedissen, A Nassif, C Modess, Z Desta, E T Ogburn, J Mostertz, M Keiser, J Jia, A Hubeny, A Ulrich, D Runge, M Marinova, D Lütjohann, H K Kroemer and W Siegmund

    Version of Record online : 1 FEB 2012, DOI: 10.1038/clpt.2011.255

  13. You have free access to this content
    Differential activation of human constitutive androstane receptor and its SV23 and SV24 splice variants by rilpivirine and etravirine

    British Journal of Pharmacology

    Volume 172, Issue 5, March 2015, Pages: 1263–1276, Devinder Sharma, Aik Jiang Lau, Matthew A Sherman and Thomas K H Chang

    Version of Record online : 10 FEB 2015, DOI: 10.1111/bph.12997

  14. You have free access to this content
    Mitochondrial (dys)function – a factor underlying the variability of efavirenz-induced hepatotoxicity?

    British Journal of Pharmacology

    Volume 172, Issue 7, April 2015, Pages: 1713–1727, M Polo, F Alegre, H A Funes, A Blas-Garcia, V M Victor, J V Esplugues and N Apostolova

    Version of Record online : 8 JAN 2015, DOI: 10.1111/bph.13018

  15. Are Literature References Sufficient for Dose Recommendations? An FDA Case Study of Efavirenz and Rifampin

    The Journal of Clinical Pharmacology

    Volume 48, Issue 4, April 2008, Pages: 518–523, Dr Jennifer L. DiGiacinto, Dr Kirk M. Chan-Tack, Dr Sarah M. Robertson, Dr Kellie S. Reynolds and Dr Kimberly A. Struble

    Version of Record online : 7 MAR 2013, DOI: 10.1177/0091270008315308

  16. Markov model for characterizing neuropsychologic impairment and Monte Carlo simulation for optimizing efavirenz therapy

    The Journal of Clinical Pharmacology

    Volume 55, Issue 11, November 2015, Pages: 1229–1235, Kuteesa R. Bisaso, Jackson K. Mukonzo and Ene I. Ette

    Version of Record online : 19 JUN 2015, DOI: 10.1002/jcph.533

  17. Effect of Rifampicin and CYP2B6 Genotype on Long-Term Efavirenz Autoinduction and Plasma Exposure in HIV Patients With or Without Tuberculosis

    Clinical Pharmacology & Therapeutics

    Volume 90, Issue 3, September 2011, Pages: 406–413, E Ngaimisi, S Mugusi, O Minzi, P Sasi, K-D Riedel, A Suda, N Ueda, M Janabi, F Mugusi, W E Haefeli, L Bertilsson, J Burhenne and E Aklillu

    Version of Record online : 3 AUG 2011, DOI: 10.1038/clpt.2011.129

  18. You have full text access to this OnlineOpen article
    Artemether-lumefantrine co-administration with antiretrovirals: population pharmacokinetics and dosing implications

    British Journal of Clinical Pharmacology

    Volume 79, Issue 4, April 2015, Pages: 636–649, Richard M. Hoglund, Pauline Byakika-Kibwika, Mohammed Lamorde, Concepta Merry, Michael Ashton, Warunee Hanpithakpong, Nicholas P. J. Day, Nicholas J. White, Angela Äbelö and Joel Tarning

    Version of Record online : 23 MAR 2015, DOI: 10.1111/bcp.12529

  19. Pharmacokinetic Interaction Between Voriconazole and Efavirenz at Steady State in Healthy Male Subjects

    The Journal of Clinical Pharmacology

    Volume 48, Issue 1, January 2008, Pages: 73–84, Mr Ping Liu, Dr Grover Foster, Mr Rober R. LaBadie, Dr Mari J. Gutierrez and Dr Amarnath Sharma

    Version of Record online : 7 MAR 2013, DOI: 10.1177/0091270007309703

  20. Artemisinin–a possible CYP2B6 probe substrate?

    Biopharmaceutics & Drug Disposition

    Volume 30, Issue 5, July 2009, Pages: 265–275, Sara Asimus and Michael Ashton

    Version of Record online : 25 JUN 2009, DOI: 10.1002/bdd.665